Science

Selecting innovative drug targets to build a pipeline of development programs


Focusing on small molecule drug discovery, Proximagen selects innovative drug targets to build a pipeline of development programs, each with the potential to provide a significant advance in the treatment of CNS and related disorders.

To more quickly and efficiently optimize new potential candidate drugs (CDs), we have in-house teams for each of the key disciplines needed for small molecule drug discovery, enabling close interaction and rapid decision-making. These teams include:

  • Medicinal chemistry
  • Biology
  • Drug metabolism and pharmacokinetics (DMPK)
  • Early Stage Development